WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H585081
CAS#: 278798-78-0
Description: R 101933 is a P-glycoprotein (P-gp) inhibitor.
Hodoodo Cat#: H585081
Name: R 101933
CAS#: 278798-78-0
Chemical Formula: C37H38N4O3
Exact Mass: 586.29
Molecular Weight: 586.736
Elemental Analysis: C, 75.74; H, 6.53; N, 9.55; O, 8.18
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: R 101933; R101933; R-101933
IUPAC/Chemical Name: 3H-Imidazo(2,1-b)(3)benzazepine-3-carboxylic acid, 2,5,6,11-tetrahydro-11-(1-(2-(4-(2-quinolinylmethoxy)phenyl)ethyl)-4-piperidinylidene)-, methyl ester
InChi Key: QPGHEZZVRGUCDN-UHFFFAOYSA-N
InChi Code: InChI=1S/C37H38N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,34H,16-25H2,1H3
SMILES Code: O=C(C1CN=C2N1CCC3=CC=CC=C3/C2=C4CCN(CCC5=CC=C(OCC6=NC7=CC=CC=C7C=C6)C=C5)CC\4)OC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 586.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Joshi P, Vishwakarma RA, Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017 Sep 29;138:273-292. doi: 10.1016/j.ejmech.2017.06.047. Epub 2017 Jun 27. Review. PubMed PMID: 28675836.
2: Lubberink M. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography. Curr Pharm Des. 2016;22(38):5786-5792. Review. PubMed PMID: 27494063.
3: Froklage FE, Boellaard R, Bakker E, Hendrikse NH, Reijneveld JC, Schuit RC, Windhorst AD, Schober P, van Berckel BN, Lammertsma AA, Postnov A. Quantification of 11C-Laniquidar Kinetics in the Brain. J Nucl Med. 2015 Nov;56(11):1730-5. doi: 10.2967/jnumed.115.157586. Epub 2015 Aug 20. PubMed PMID: 26294297.
4: Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):68-77. doi: 10.1002/jlcr.2993. Review. PubMed PMID: 24285312.
5: Postnov A, Froklage FE, van Lingen A, Reijneveld JC, Hendrikse NH, Windhorst AD, Schuit RC, Eriksson J, Lammertsma AA, Huisman MC. Radiation dose of the P-glycoprotein tracer 11C-laniquidar. J Nucl Med. 2013 Dec;54(12):2101-3. doi: 10.2967/jnumed.113.120857. Epub 2013 Oct 3. PubMed PMID: 24092938.
6: Syvänen S, Russmann V, Verbeek J, Eriksson J, Labots M, Zellinger C, Seeger N, Schuit R, Rongen M, van Kooij R, Windhorst AD, Lammertsma AA, de Lange EC, Voskuyl RA, Koepp M, Potschka H. [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness. Nucl Med Biol. 2013 Aug;40(6):764-75. doi: 10.1016/j.nucmedbio.2013.05.008. Epub 2013 Jul 1. PubMed PMID: 23827307.
7: Dickens D, Owen A, Alfirevic A, Pirmohamed M. ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. Pharmacogenet Genomics. 2013 Jun;23(6):314-23. doi: 10.1097/FPC.0b013e328360d10c. PubMed PMID: 23619510.
8: Chopra A. O-[(11)C]methyl derivative of 6,7-dimethoxy-2-(4-methoxy-biphenyl-4-yl-methyl)-1,2,3,4-tetrahydro-isoquinoline. 2012 Nov 5 [updated 2013 Jan 31]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK116755/ PubMed PMID: 23390669.
9: Moerman L, Dumolyn C, Boon P, De Vos F. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier. Nucl Med Biol. 2012 Jan;39(1):121-5. doi: 10.1016/j.nucmedbio.2011.06.009. Epub 2011 Sep 29. PubMed PMID: 21958857.
10: Colabufo NA, Berardi F, Perrone MG, Capparelli E, Cantore M, Inglese C, Perrone R. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr Top Med Chem. 2010;10(17):1703-14. Review. PubMed PMID: 20645922.
11: Balayssac D, Cayre A, Ling B, Maublant J, Penault-Llorca F, Eschalier A, Coudoré F, Authier N. Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neurosci Lett. 2009 Nov 6;465(1):108-12. doi: 10.1016/j.neulet.2009.09.003. Epub 2009 Sep 4. PubMed PMID: 19733628.
12: Luurtsema G, Schuit RC, Klok RP, Verbeek J, Leysen JE, Lammertsma AA, Windhorst AD. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9. doi: 10.1016/j.nucmedbio.2009.03.004. PubMed PMID: 19647170.
13: Werle M, Takeuchi H, Bernkop-Schnürch A. New-generation efflux pump inhibitors. Expert Rev Clin Pharmacol. 2008 May;1(3):429-40. doi: 10.1586/17512433.1.3.429. PubMed PMID: 24422696.
14: Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006 Jul;7(7):861-79. Review. PubMed PMID: 16842217.
15: Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51. Review. PubMed PMID: 15494300.
16: Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs. 2004 Aug;22(3):219-29. PubMed PMID: 15122069.
17: Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003 Mar-Apr;10(2):159-65. Review. PubMed PMID: 12712010.
18: van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer. 2002 May;38(8):1090-9. PubMed PMID: 12008197.
19: Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5. Review. PubMed PMID: 11990784.
20: Yamamoto W, Verweij J, de Bruijn P, de Jonge MJ, Takano H, Nishiyama M, Kurihara M, Sparreboom A. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs. 2001 Jun;12(5):419-32. PubMed PMID: 11395570.
